Storyline

New gene signatures reveal prognostic insights and therapeutic targets in glioblastoma and colorectal cancer

Recent studies have identified key gene signatures linked to prognosis and treatment resistance in glioblastoma (GBM) and colorectal cancer (CRC).

Published 2026-05-18 17:58 UTCUpdated 2026-05-20 16:52 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (1 domains)domains are deduped. counts indicate coverage, not truth.
1 top source shown
limited source diversity in top sources
Overview

Recent studies have identified key gene signatures linked to prognosis and treatment resistance in glioblastoma (GBM) and colorectal cancer (CRC).

Score total
0.73
Momentum 24h
2
Posts
2
Origins
1
Source types
1
Duplicate ratio
0%
Why now
  • Recent integrative analyses leverage large single-cell and multi-cohort datasets.
  • Bevacizumab resistance remains a major clinical challenge in colorectal cancer.
  • Understanding molecular pathways can accelerate development of targeted therapies.
Why it matters
  • Identifies novel prognostic biomarkers for glioblastoma and colorectal cancer.
  • Highlights potential therapeutic targets including NTN1 and bevacizumab resistance genes.
  • Supports personalized medicine approaches by revealing sex-specific and resistance-associated molecular signatures.
Continuity snapshot
  • Trend status: insufficient_history.
  • Continuity stage: seed.
  • Current status: open.
  • 2 current source-linked posts are attached to this storyline.
All evidence
Show filters & breakdown
Posts loaded: 0Publishers: 1Origin domains: 1Duplicates: -
Showing 1 / 0
Top publishers (this list)
  • bioRxiv (all subjects) (1)
Top origin domains (this list)
  • biorxiv.org (1)